Date: 2013-04-18
Type of information: Fundraising
Company: Allecra Therapeutics (Germany - France)
Investors: Forbion Capital Partners (The Netherlands) Edmond de Rothschild Investment Partners (France) EMBL Ventures (Germany)
Amount: €15 million
Funding type: Series A financing round
Planned used: The Series A financing will be used to support early clinical development of two new antibiotic treatments designed to combat multi drug-resistant gram-negative bacteria.
Others: Forbion Capital Partners, the Dutch life sciences venture capital firm, has announced that it has co-led the €15 million Series A financing round for Allecra Therapeutics GmbH, together with Edmond de Rothschild Investment Partners. EMBL Ventures was also part of the syndicate. Allecra was formed in 2013 as a strategic partnership between the Company’s founders including Nicholas Benedict, CEO, working in conjunction with Orchid Chemicals & Pharmaceuticals Limited (Chennai, India) and the two lead investors. Allecra is a biopharmaceutical company dedicated to the development of novel antibiotics to combat multi drug-resistant bacterial infections.
Therapeutic area: Infectious diseases
